J Acquir Immune Defic Syndr by Widen, Elizabeth M et al.
Antiretroviral treatment is associated with iron deficiency in HIV-
infected Malawian women that is mitigated with 
supplementation, but is not associated with infant iron 
deficiency during 24 weeks of exclusive breastfeeding
Elizabeth M Widen, Margaret E Bentley, Charles S Chasela, Dumbani Kayira, Valerie L Flax, 
Athena P Kourtis, Sascha R Ellington, Zebrone Kacheche, Gerald Tegha, Denise J 
Jamieson, Charles M van der Horst, Lindsay H Allen, Setareh Shahab-Ferdows, and Linda 
S Adair for the BAN Study Team
Columbia University, New York, NY, USA (E M Widen PhD, RD); University of North Carolina at 
Chapel Hill, Chapel Hill, NC, USA (M E Bentley PhD, V L Flax PhD, C van der Horst MD, L S 
Adair PhD); University of Witwatersrand, Parktown, South Africa (C S Chasela PhD); UNC 
Project, Lilongwe, Malawi (D Kayira MBBS, Z Kacheche BSc, G Tegha BSc); US Centers for 
Disease Control and Prevention, Atlanta, GA, USA (A P Kourtis MD, S E Ellington MSPH, D J 
Jamieson MD); US Department of Agriculture, Agricultural Research Service - Western Human 
Nutrition Research Center, Davis, CA, USA (L H Allen PhD, S Shahab-Ferdows PhD)
Abstract
Objective—In resource-limited settings without safe alternatives to breastfeeding, the WHO 
recommends exclusive breastfeeding and antiretroviral (ARV) prophylaxis. Given the high 
prevalence of anemia among HIV-infected women, mothers and their infants (via fetal iron 
accretion) may be at risk of iron deficiency. We assessed the effects of maternal micronutrient-
fortified lipid-based nutrient supplements (LNS) and maternal ARV treatment or infant ARV 
prophylaxis on maternal and infant iron status during exclusive breastfeeding from birth to 24 
weeks.
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Methods—The Breastfeeding, Antiretrovirals, and Nutrition Study was a randomized controlled 
trial conducted in Lilongwe, Malawi from 2004-2010. HIV-infected mothers (CD4>200 cells/ul) 
and their infants were randomly assigned to 28-week interventions: maternal-LNS/maternal-ARV 
(n=424), maternal-LNS/infant-ARV (n=426), maternal-LNS (n=334), maternal-ARV (n=425), 
infant-ARV (n=426), or control (n=334). Longitudinal models tested intervention effects on 
hemoglobin (Hb). In a subsample (n=537) with multiple iron indicators, intervention effects on 
Hb, transferrin receptors (TfR) and ferritin were tested with linear and Poisson regression.
Results—In longitudinal models, LNS effects on maternal and infant Hb were minimal. In 
subsample mothers, maternal ARVs were associated with tissue iron depletion (TfR>8.3 mg/L) 
(Risk ratio (RR): 3.1, p<0.01), but not in ARV-treated mothers receiving LNS (p=0.17). LNS 
without ARVs, was not associated with iron deficiency or anemia (p>0.1). In subsample infants, 
interventions were not associated with impaired iron status (all p-values>0.1).
Conclusions—Maternal ARV treatment with protease inhibitors is associated with maternal 
tissue iron depletion; but LNS mitigates adverse effects. ARVs do not appear to influence infant 
iron status; however, extended use needs to be evaluated.
Introduction
In resource-poor settings, the WHO recommends that HIV-infected women exclusively 
breastfeed for six months and continue breastfeeding to twelve months.1 In this population, 
antiretrovirals (ARV) are provided to the mother or infant to prevent mother-to-child 
transmission of HIV (PMTCT) if replacement feedings are not acceptable, feasible, 
affordable, sustainable and safe.1 HIV-infected women are at risk of impaired iron status 
during pregnancy and postpartum due to heightened iron demands in this period coupled 
with the demands of the HIV-infection.2-5 Given the strong influence of maternal iron status 
on infants’ iron endowment at birth and thus subsequent iron status,6 infants born to HIV-
infected mothers are at high risk of iron deficiency.7,8
Some prenatally-administered ARVs, especially zidovudine, are associated with maternal 
anemia9 and severe infant anemia postpartum.10 This is in contrast to findings in non-
pregnant adult populations, where initiation of highly active antiretorviral therapy (HAART) 
is associated with increases in hemoglobin.11-13 While some studies have shown that single-
dose infant nevirapine may have transient effects on infant iron status,14,15 extended infant 
nevirapine regimens do not appear to influence short and long-term risk of anemia.16,17 
However, data regarding the effects of extended postpartum PMTCT regimens on maternal 
and infant iron status are limited and no studies to date have reported results among mothers 
also receiving nutritional supplementation.
The Breastfeeding, Antiretrovirals, and Nutrition (BAN) study was a randomized-controlled 
trial designed to test interventions for PMTCT.17 Mother-infant pairs were randomized with 
a two-by-three factorial design to one of six 28-week treatment assignments: three 
antiretroviral groups (maternal ARV, infant nevirapine or no extended postnatal ARV) and 
two maternal nutritional intervention groups [lipid-based nutrient supplements (LNS) or no 
LNS]. Previously, we reported that the proportion of low hemoglobin (Hb) (Grade 3 or 4 
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adverse events) in both mothers and infants did not differ by ARV group; however, this 
analysis did not evaluate effects of LNS.17
This secondary analysis explores the effects of the six treatments on 1) maternal and infant 
hemoglobin (Hb) longitudinally during exclusive breastfeeding and in a subsample with 
multiple iron indicators 2) maternal and infant ferritin, transferrin receptors (TfR) and Hb, 
adjusted for the acute-phase response. We hypothesized that ARVs would be associated with 
worsening maternal and infant iron indicators, and that LNS would be associated with 
improved maternal iron indicators. We did not expect to observe LNS effects in the infants 
because previous evidence suggests that maternal iron supplementation during breastfeeding 
does not influence infant iron status.18
Methods
Participants
Data are from the BAN Study (Clinical trials.gov number NCT00164736), conducted from 
2004-2010, whose design 19 and primary intervention findings have been previously 
reported.17,20-22 Briefly, HIV-1-infected pregnant women (n=3572) were recruited from 
antenatal clinics in Lilongwe, Malawi. Primary eligibility criteria for initial enrollment 
included: gestational age ≤ 30 weeks, CD4 ≥250 cells/μL (CD4 ≥200 cells/μL before July 
2006), Hb ≥70 g/L. After delivery, secondary eligibility criteria for randomization included: 
infant birth weight ≥2 kg, and no previous ARV use.19 Infants diagnosed with HIV-1 within 
two weeks of delivery were withdrawn from the study and referred for care.17
Ethical Approval
The Malawi National Health Science Research Committee and the institutional review 
boards at the University of North Carolina at Chapel Hill and the U.S. Centers for Disease 
Control and Prevention provided ethical approval for the study, and the institutional review 
board at the University of California, Davis approved the laboratory analyses at the Western 
Human Nutrition Research Center. Written informed consent was obtained from all study 
mothers.
Randomization
At delivery, mother-infant dyads (n=2369) were randomized to one of six 28-week treatment 
arms: maternal LNS/maternal ARV (mLNS-mARV), maternal LNS/infant ARV (mLNS-
iARV), maternal LNS only (mLNS), maternal ARV only (mARV), infant ARV only 
(iARV), or control.
Study interventions
All mothers received daily iron-folic acid supplementation containing 40 mg elemental iron 
and 0.25 mg folic acid from the initial screening to 1 week postpartum. All mothers and 
infants also received an intrapartum single dose of nevirapine and twice daily zidovudine 
and lamivudine for seven days after delivery.14
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Mothers assigned to the nutritional intervention were given 140 grams of LNS per day, 
providing 746 kcal, 20.8 g protein and 15 mg of elemental iron (supplemental table 1).22 To 
prevent sharing of LNS, all mothers were provided maize for family consumption.22 The 
maternal antiretroviral regimen initially consisted of zidovudine, lamivudine, and 
nevirapine. Nelfinavir replaced nevirapine after the first 39 women were randomized, and 
lopinavir/ritonavir replaced nelfinavir shortly thereafter, with most (>75%) mothers 
randomized to ARV receiving zidovudine/lamivudine/lopinavir-ritonavir. Infants 
randomized to ARV received daily oral nevirapine (details previously reported17. Starting 
on June 13, 2006, cotrimoxazole prophylaxis (CPT) (240 mg once daily) was provided to all 
infants >6 weeks old and initiated for all mothers with a CD4<500 cells/uL in pregnancy;23 
in this report 68% and 43% of infants and mothers received CPT, respectively. In March 
2008, the data safety monitoring board at the National Institute of Allergy and Infectious 
Diseases reviewed data from the enrolled 1857 mother-infant pairs and observed that HIV 
transmission through breast milk was higher in the no-drug study arms.24 Enrollment was 
halted in these groups and mothers in these arms were allowed to choose to switch to the 
maternal or infant ARVs, or remain in the control group.24
Mothers were provided additional iron supplementation as clinically indicated or with ≥ 
moderate anemia (Hb≤84 g/L25). Records of additional iron supplementation were 
abstracted from medication, severe adverse event and morbidity forms, linked to 
concomitant study visit(s). Few participants (<3%) were given supplemental iron.
Study visits were conducted at the BAN Study clinic in Lilongwe, Malawi at birth, 1, 2, 4, 6, 
8, 12, 18, 21, and 24 weeks postpartum. This analysis includes data from 0-24 weeks, when 
mothers were provided with intensive counseling to exclusively breastfeed.26,27 Maternal 
Hb was measured at prenatal screening and maternal and infant Hb (g/L) was measured at 
birth, 2, 6, 12, 18 and 24 weeks postpartum from venous blood samples with a Beckman 
Coulter AcT or AcT 5-part Differential Analyzer (Beckman Coulter, Fullerton, CA). Infant 
HIV status was tested with Amplicor 1.5 DNA polymerase-chain reaction. Measurements 
included maternal and infant weights with regularly calibrated Tanita digital scales, infant 
length with a recumbent length board, and maternal height with a wall-mounted stadiometer. 
At screening, maternal report of parity, marital status and education was obtained. Exclusive 
breastfeeding was obtained by maternal report.
Plasma for additional biomarker assays was separated from red blood cells, aliquoted to 1 
mL polypropylene storage tubes, and stored at -70°C. Briefly, subsample laboratory 
analyses used plasma obtained at either 2 or 6 weeks, as many infants had insufficient 
plasma at 2 weeks, and 24 weeks postpartum. Transferrin receptors (TfR) and inflammatory 
marker [C-reactive protein (CRP) and α-1-acid glycoprotein (AGP)] concentrations were 
measured using Cobas Integra 400 (Roche Diagnostics, Indianapolis, IN).28 Ferritin 
concentrations were measured with IRMA Ferritin Coat a Count radioimmunoassay 
(Siemens Health Care Diagnostics Inc., Plainfield, IN).28
Statistical analysis
The primary outcomes for this analysis are maternal and infant Hb, ferritin and TfR. The 
primary independent variables are the study intervention arms. For the maternal outcomes, 
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four intervention groups were evaluated; mothers of infants receiving ARVs (mLNS-iARV 
and iARV) were included in the mLNS and control groups, respectively (supplemental 
figure 1). Mother-infant pairs were excluded from both analysis samples if the infant was a 
multiple birth (n=49), which may influence fetal iron accretion, or HIV-infected from 2-24 
week (n=57), which may influence iron mobilization and interpretation of iron indicators.29 
Observations after breastfeeding cessation (n=277) were dropped in longitudinal analyses, as 
cessation would influence maternal nutritional status and the infant would no longer be 
exposed to maternal ARVs through breast milk. Of the 2369 randomized dyads, 1765 and 
1927 were included in the longitudinal maternal and infant analytic samples, respectively 
(Supplemental figure 2). Subsample dyads (n=537) were selected with equal representation 
from the LNS and no-LNS groups, prioritizing those with anthropometry and dietary data 
and excluding multiple births and HIV-positive infants (Supplemental figure 
3).28Characteristics of included and excluded dyads in each analytic sample were compared 
for similarity using t-tests and nonparametric tests for normally-distributed and skewed 
continuous variables, respectively. Similar tests compared characteristics of those only in the 
longitudinal sample versus the subsample. Because a small number of mothers in this 
analysis received additional iron supplementation, we evaluated whether supplementation 
varied by treatment arm, and observed no differences across treatment arms at each visit (all 
p>0.19; data not shown). STATA 12.0 (College Station, TX) was used for all statistical 
analyses. An α of 0.05 denoted statistical significance.
Infants were included in the longitudinal analyses if they had birth weight and Hb at birth, 
and at least one other Hb measurement. Mothers were included in the longitudinal analysis if 
they had Hb at 2 weeks postpartum and at least one other measurement. Due to hematologic 
dilution at delivery and inflammation of parturition30, which would distort initial 
measurements, maternal models utilized the 2-week Hb value as baseline. Longitudinal 
random effects models with first order autoregressive disturbance terms were used to 
evaluate the effect of the study interventions on (1) maternal Hb from 6 to 24 weeks 
postpartum and (2) infant Hb from 2 to 24 weeks, adjusting for week and initial Hb.31 Infant 
models were further adjusted for birth weight, growth rate and sex. In infant models, age 
was modeled in weeks and included a knot at 9 weeks of age to capture the shape of the 
infant Hb curve over time. To determine whether intervention effects varied with infant age, 
interactions of week with covariates were evaluated using Wald tests for joint significances 
(α of 0.132) and significant interaction terms were retained.
In the subsample, we accounted for the acute-phase response and minimized the effects of 
the infection (such as malaria and HIV) and inflammation [elevated CRP (>5 mg/L) and 
AGP (>1 g/L)] on TfR, Hb and ferritin.28 Stage of inflammation [healthy (normal CRP & 
AGP), incubation (elevated CRP), early convalescence (CRP & AGP elevated), late 
convalescence (elevated AGP)] and stage specific correction factors were 
determined.28,33,34 Plasma ferritin and TfR had non-Gaussian distributions and were log-
transformed for analyses. Linear regression was used to evaluate the effects of study 
interventions on maternal and infant iron status (ferritin and TfR) and Hb. Modified Poisson 
regression with robust variance estimators was used to estimate relative risk of maternal and 
infant deficiency or anemia at 24 weeks.35 For all models, sensitivity analyses were 
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conducted to evaluate whether inclusion of an indicator variable for maternal iron 
supplementation or CPT influenced the study intervention effects.
Results
Maternal
Most baseline maternal characteristics were well balanced by study arm for the longitudinal 
sample and the subsample (table 1). A smaller proportion of control mothers were married 
or educated beyond primary school in the longitudinal sample (table 1). Compared to 
randomized mothers not included in this analysis, mothers in both analytic samples were 
older, more educated, had higher pregnancy Hb, and lower BMI at delivery. Compared to 
mothers only in the longitudinal sample, mothers in both analytic samples had lower BMI at 
delivery (data available in online supplemental materials).
Maternal Hb increased from baseline to 24 week (figure 1) and thus prevalence of anemia 
(Hb <120 g/L, unadjusted for inflammation) decreased. In subsample mothers, prevalence of 
tissue iron depletion (TfR >8.3 mg/L) declined, while prevalence of depleted iron stores 
(Ferritin <15 ng/ml) remained somewhat stable (table 2).
In the longitudinal analysis, mLNS had no effects on maternal Hb (table 3). There were 
some transient effects of maternal ARVs on maternal Hb (table 3). Based on linear 
combinations of the beta coefficients for the intervention groups and weeks, maternal Hb 
was significantly lower at 6 and 12 weeks, but not at subsequent observations, in mothers 
who received mLNS-mARV (6 wk β: -3.21g/L (95% CI: -4.46, -1.94), p<0.001); 12 wk β: 
-1.88 g/L (95% CI: -2.91, -0.85), p<0.001) or mARV (6 wk β: -2.11 g/L (95% CI: -3.35, 
-0.87), p=0.001); 12 wk β: -1.47g/L (95% CI: -2.50, -0.45, p=0.005) (table 3).
In subsample mothers, mLNS was not associated with maternal Hb, TfR, or ferritin, 
compared to control (all p-values >0.1) (supplemental table 2). mARV and mLNS-mARV 
were associated with lower Hb at 6 weeks and higher TfR at 6 and 24 weeks (indicative of 
worsening iron status), but were not associated with ferritin (supplemental table 2). Even 
though the interventions were not associated with risk of maternal anemia (Hb <120 g/L) or 
depleted iron stores (ferritin <15 ng/ml) at 24 weeks, mARV was associated with increased 
risk of tissue iron depletion (TfR >8.3 mg/L) but only in ARV treated-mothers who did not 
receive LNS (table 4). Although continuous TfR values were higher in mothers in the 
mLNS-mARV group at 24 weeks (supplemental table 2), mothers in this group were not at 
higher risk of tissue iron depletion compared to controls. In sensitivity analyses, adjustment 
for additional maternal iron supplementation and CPT had no or negligible changes on 
intervention effects (data not shown).
Infant
Baseline infant characteristics were well balanced across the study arms (table 1). Compared 
to other randomized dyads, infants in both analytic samples were heavier at birth and more 
likely to be in the iARV arms (data available in online supplemental materials).
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Mean infant Hb followed the normal pattern of decline from a high of above 170 g/L at birth 
to a nadir at about 8 weeks, as senescent fetal Hb lyses, with a subsequent slight increase 
thereafter (figure 1).29 In subsample infants, ferritin values declined from initial 
measurement to 24 weeks, as values normalized following erythrocyte breakdown, whereas 
TfR increased. Few infants had impaired iron status based on measurements at birth or 2/6 
or 24 weeks, but at 24 weeks worsening iron status was apparent (table 2).
In the longitudinal analytic sample, minimal intervention effects were observed on infant Hb 
(supplemental table 3). Based on linear combinations of the beta coefficients for each 
intervention arm and age, mLNS-iARV was associated with 2.8 g/L (p=0.03) lower Hb at 6 
weeks; but was not associated with lower Hb values at later visits [12 wk β: -2.51 g/L (95% 
CI: -5.16, 0.15), p=0.06; 18 wk β: -0.97 g/L (95% CI: -3.44, 1.51), p=0.44; 24 wk β: 0.57 
g/L (95% CI: -2.25, 3.39), p=0.7] (supplemental table 3). In the subsample infants where Hb 
was corrected for inflammation, however, some intervention effects on continuous Hb 
values were observed. Though mLNS had no effect on Hb at 2 or 6 weeks, it was associated 
with lower infant Hb at 24 weeks (supplemental table 2). Compared to controls, mLNS-
iARV and iARV were associated with lower Hb values at 2 and 24 weeks (β range: 4-5 g/L), 
while a similar but non-significant trend was observed at 6 weeks (β range: 4.3-5.3 g/L) 
(supplemental table 2).
At 24 weeks, mLNS was associated with lower infant ferritin values (supplemental table 2). 
mLNS and mLNS-mARV were associated with higher infant TfR at 2 weeks, but not at 
other times. The interventions were not associated with risk of infant iron deficiency 
(Inflammation adjusted Ferritin <12 ng/ml; TfR >8.3 mg/L) or anemia (Inflammation 
adjusted Hb <105 g/L) at 24 weeks (Table 4). In sensitivity analyses, adjustment for 
additional maternal iron supplementation or infant CPT did not influence intervention 
effects on infant Hb or iron status (data not shown).
Discussion
To our knowledge, this is the first study to investigate effects of extended ARVs coupled 
with maternal nutrition supplementation on maternal and infant iron status during exclusive 
breastfeeding. Our results suggest that maternal ARV therapy and infant nevirapine 
prophylaxis were associated with worsening of some maternal and infant iron status 
indicators. Most notably, maternal ARVs were associated with a three-fold risk of tissue iron 
depletion, but this risk was mitigated by mLNS, where adverse effects on tissue iron 
depletion (TfR levels) were reduced. Although the mLNS contained only 15 mg of iron, this 
amount was sufficient to mitigate some of the adverse ARV effects on maternal tissue iron 
status. Interestingly, the interventions did not impact risk of maternal iron store depletion 
(low ferritin) or anemia. Tissue iron depletion reflects more severe iron deficiency, as TfR 
levels increase when ferritin values become subnormal (e.g. iron stores are depleted); 
therefore, populations can have depleted iron stores before tissue iron depletion is apparent. 
Maternal supplementation had few clinically meaningful or sustained effects on infant TfR, 
Hb or ferritin, and neither the mLNS nor maternal or infant ARVs were associated with 
increased risk of infant iron deficiency or anemia at 24 weeks..
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Several randomized trials and cohort studies have demonstrated adverse effects of 
antiretrovirals on maternal or infant iron status, particularly zidovudine-containing 
regimens;9,14,16,36-45 however, none, other than ours,17 evaluated extended postnatal ARV 
regimens coupled with a nutritional supplement. Furthermore, none of these trials evaluated 
multiple iron status indicators, nor did they account for the effect of inflammation and 
infection on iron status. In HIV affected populations anemia of inflammation is common, 
defined as presence of inflammation without iron deficiency anemia, and initiation of 
antiretroviral therapy may differentially impact indicators of iron status (increase TfR and 
Hb); thus measurement of the acute phase response to correct iron indicators for concurrent 
inflammation/infection is recommended for assessment of iron status.46 With inflammation 
and infection, iron status indicators are distorted; plasma ferritin levels are falsely elevated 
and do not reflect body iron stores, while Hb levels are lowered.46 TfR may be increased 
with iron deficiency anemia in the presence of inflammation; 46 but it is believed to be less 
sensitive to the effects of anemia of inflammation/infection than other indicators. Previously 
in BAN we observed associations between inflammatory markers and TfR, ferritin and 
Hb28; therefore, in our subsample analyses, we used methods recommended by Thurnham to 
mitigate the effects of the acute phase response on iron status indicators.34
This is the first study to use longitudinal data with a true control group to report hematologic 
effects of maternal ARV exposure on multiple postpartum iron-indicators. In a cohort study 
of pregnant HIV-infected women in Thailand anemia (Hb < 94 g/L) was significantly 
associated with HAART use compared to antiretrovirals for PMTCT with both regimens 
containing zidovudine (p=0.02).9 Another cohort study in Italy compared hematologic 
outcomes of antiretrovirals in three groups 1) women receiving zidovudine-based HAART 
from conception, 2) women starting zidovudine-based HAART during pregnancy, and 3) 
women receiving zidovudine-free HAART from conception.36 Women receiving 
zidovudine-free HAART had a greater decrease in Hb from baseline to 36 weeks gestation 
compared to women who started a zidovudine-containing HAART regimen during 
pregnancy (-20.3 ± 11.9 g/L vs. -13.6 ± 12.0 g/L, p=0.04).36 Together these studies suggest 
that prenatal maternal Hb may be compromised by some ARV regimens, but there is 
insufficient evidence that prenatal ARVs always lead to anemia. We did not observe 
sustained adverse effects of postpartum ARVs on maternal Hb. This may reflect use of 
different ARV regimens, sample differences (BAN excluded mothers with Hb<70 g/L), or 
prenatal/postpartum period differences. While there is evidence that initiation of HAART 
(with various combinations of drugs) is associated with increased hemoglobin and/or 
improved anemia in non-pregnant populations,11-13 these results may not be comparable to 
pregnant/postpartum populations due to heightened iron demands in this period or to 
relatively healthy HIV-infected pregnant/postpartum women receiving antiretrovirals.
Several studies have indicated that ARV regimens are associated with adverse effects on 
infant Hb,10,37-45 while one study has shown some positive effects.15 Infants who received a 
short-course regimen including maternal peripartum nevirapine and/or infant zidovudine 
and/or nevirapine had higher Hb from birth to 6 months and lower prevalence of deficiency 
at 6 months.15 However, no differences in deficiency prevalence were observed beyond 6 
months.15 Adverse and often transient hematologic effects of zidovudine-containing 
antiretroviral regimens during pregnancy have been reported in numerous cohorts,10,38-43 
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with many of these cohorts reporting severe anemia in HAART-exposed infants.10,41 
Additionally, postnatal zidovudine exposure has been associated with lower infant Hb 
and/or increased infant anemia10,37,41,43,44 and may have long-lasting adverse effects on 
infant Hb up to 18 months postpartum.45 Similar to previous reports, we observed transient 
effects of maternal and infant ARVs on some infant Hb and TfR; however, we did not 
observe increased anemia or iron deficiency, which may be attributable to sample 
differences related to BAN inclusion criteria, type and timing of initiation of ARVs (infants 
in BAN were not exposed to ARVs in utero), and close follow up, as well as our report of 
additional iron indicators and adjustment for inflammation.
While no prior studies reported effects of maternal LNS on maternal or infant iron status, 
one study examined the effects of multivitamin supplementation during pregnancy and 
postpartum on maternal and infant iron status in the context of HIV.36 In a Tanzanian cohort 
of ARV-naive and predominately anemic HIV-infected women who received standard iron 
and folic acid supplementation during pregnancy (containing 120 mg iron and 5 mg folic 
acid), maternal multivitamin supplementation, containing no iron, starting prenatally and 
continuing through lactation was associated with 8.8 g/L (p=0.0002) higher maternal 
hemoglobin (Hb) at ≤70 days postpartum compared to placebo. 47 The authors speculated 
that vitamins in the supplement, especially vitamin C, may have contributed to better iron 
status and enhanced absorption of dietary iron.47 While we did not observe effects of this 
magnitude in our mothers, who started receiving supplementation postpartum, mLNS was 
associated with reduced tissue iron depletion in mother’s receiving ARVs. Infant Hb 
outcomes in this Tanzanian population were not significantly different between 
supplementation groups at six months, infant Hb was 3.1 g/L and 2.9 g/L higher at 2 and 4 
years, respectively, for infants whose mothers received supplementation compared to 
placebo.47 In our study at 24 wk (approximately 6 mo), maternal LNS, with and without 
infant ARV therapy (mLNS and mLNS-iARV), was associated with approximately 4-5 g/L 
lower infant Hb at 24 wk, which contradicts the 6 mo findings in the Tanzanian sample.47 
These differences may be due to varying time periods of supplementation (LNS in our 
sample was initiated postpartum) or our ability to account for the effects of inflammation/
infection on Hb values.
There are several limitations to this work. Initial subsample measurements were obtained at 
2 or 6 weeks postpartum due to insufficient plasma at 2 weeks. This reflects varying periods 
of exposure to the interventions; therefore, we evaluated for intervention effects separately 
at each visit in the subsample analyses. Compared to all randomized infants, included infants 
were healthier and worse off infants (including those with HIV-infection) and mothers were 
lost to follow-up or excluded from analyses. As such, our ability to detect intervention 
effects may be reduced. Some mothers received iron supplementation when clinically 
indicated; however, sensitivity analyses showed that this did not change our interpretation of 
intervention effects. Lastly, our findings may not be generalizable to other populations of 
HIV-infected women and their HIV-exposed infants, as mothers with low CD4 counts and 
previous ARV exposure were excluded from BAN and also due to our selection criteria for 
longitudinal analysis. Dyads were closely followed by study staff and promptly treated for 
adverse events and other illnesses.
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The WHO now recommends that HIV-infected mothers or their uninfected infants receive 
antiretroviral prophylaxis during twelve months of breastfeeding.1 Given these revised 
recommendations, the nutritional demands of lactation and HIV, 48 and the adoption of 
lifelong antiretroviral therapy for pregnancy and lactating HIV-infected women (Option B
+), maternal LNS or possibly another iron supplementation method (e.g. iron-folic acid) may 
be valuable to support lactation and prevent impaired iron status and associated 
consequences such as elevated risk of maternal or infant mortality and maternal HIV-disease 
progression.5,7,8 However, in settings with endemic malaria, iron supplementation may be 
associated with increased risk of malaria,49,50 thus supplementation should be coupled with 
malaria prevention, diagnosis and treatment efforts. Future randomized controlled trials are 
needed to examine the effects of antiretroviral regimens beyond six months and to establish 
the optimal composition of supplementation to minimize possible adverse effects of 
extended antiretroviral regimens. If adverse effects of extended regimens on iron status are 
observed in clinical trials, it may be possible to provide supplementation along with ARV 
therapy to support maternal health and micronutrient status through Option B+ 
programming. Further evidence, however, is needed to establish the feasibility and 
acceptability of providing maternal supplementation in conjunction with antiretroviral 
therapy and malaria diagnosis, prevention and treatment efforts.
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Figure 1. 
(A) Mean maternal hemoglobin (g/L) values according to BAN study arm from birth to 24 
weeks among HIV-infected Malawian mothers in the longitudinal sample (n=569 in the 
control arm; n=315 in the mARV arm; n=573 in the mLNS arm; n=308 in the maternal 
ARV-LNS arm). (B) Mean infant hemoglobin (g/L) values according to BAN study arm 
from birth to 24 weeks among HIV-exposed Malawian infants in the longitudinal sample. 
BAN Study, Malawi, 2004-2010. (n=341 in the mLNS-mARV arm; n=339 in the mARV 
arm; n=369 in the mLNS-iARV arm; n=356 in the iARV arm; n=255 in the mLNS arm; 
n=267 in the control arm). mLNS-mARV, maternal LNS/maternal ARV; mARV, maternal 
ARV; mLNS-iARV, maternal LNS/infant ARV; iARV, infant ARV; mLNS, maternal LNS; 
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C, control. BAN, Breastfeeding, Antiretroviral and Nutrition; LNS, lipid-based nutrient 
supplement; ARV, antiretroviral drug.
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Table 2
Infection and inflammation adjusted iron status indicators in HIV-infected Malawian mothers and HIV-
exposed infants in the BAN Study subsample, 2004-2010 1,2
Initial measurement 24 weeks
2 weeks 6 weeks
Maternal
 Hb(g/L)3 125.5 ± 16.1 (360) 122.1 ± 13.4 (170) 125.5 ± 11.5 (534)
  Low (%)4 35.3 38.8 29.6
 Ferritin (ng/mL)3 29.98 ± 37.26 (362) 43.09 ± 63.69 (170) 32.38 ± 43.08 (536)
  Deficient (%)4 39.2 32.4 33.4
 TfR (mg/L)3 5.69 ± 2.82 (362) 5.67 ± 3.50 (170) 4.86 ± 2.27 (535)
  Deficient (%)4 12.7 15.9 6.9
 Elevated inflammatory markers
  CRP >5 mg/L (%) 42.9 22.4 16.4
  AGP >1 g/L (%) 76.8 47.7 33.5
Infant
 Hb (g/L)3 143.0 ± 17.8 (351) 111.4 ± 12.8 (163) 104.7 ± 11.0 (526)
  Low (%)5 -6 -6 51.7
 Ferritin (ng/mL)3 462.68 ± 338.66 (359) 314.67 ± 228.92 (167) 42.34 ± 102.80 (533)
  Deficient (%)5 2.0 6.0 31.0
 TfR (mg/L)3 3.53 ± 1.90 (360) 3.35 ± 1.91 (165) 6.64 ± 3.33 (531)
  Deficient (%)5 1.7 3.0 21.9
 Elevated inflammatory markers
  CRP >5 mg/L (%) 8.9 16.2 28.5
  AGP >1 g/L (%) 8.6 16.1 47.0
1
BAN, Breastfeeding Antiretrovirals and Nutrition Study; Hb, serum hemoglobin; TfR, plasma soluble transferrin receptor; CRP, plasma C-
reactive protein; AGP, plasma α1-acid glycoprotein.
2Adjusted for inflammation by using group specific correction factors estimated from ratios of medians for the various iron indicators34,35
3Values are Mean ± SD (n)
4
Low maternal Hb <120 g/L2, abnormal ferritin <15 ng/mL, abnormal TfR>8.3 mg/L
5
Low infant Hb was defined as <105 g/L at 24 weeks25. Abnormal infant TfR >8.3 mg/L and ferritin <30 ng/mL at 2/6 weeks and <12 ng/mL at 
24 weeks.
6Cutpoints for low infant Hb are not available <3 months of age
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Table 3
Longitudinal random effects model showing the associations between the study intervention arm sand 
maternal Hb outcomes (g/L) from 6 to 24 weeks in 1765 HIV-infected Malawian mothers in the BAN Study, 
2004-20101
Coef. 95% Confidence Interval p-value
Maternal Hb at 2 week 0.51 [0.49, 0.54] <0.001
Week 0.15 [0.10, 0.20] <0.001
mLNS-mARV -4.49 [-6.17, -2.80] <0.001
mARV -2.70 [-4.38, -1.03] 0.002
mLNS -0.11 [-1.52, 1.30] 0.88
mLNS-mARV*Week 0.22 [0.13, 0.31] <0.001
mARV*Week 0.10 [0.01, 0.19] 0.03
mLNS*Week 0.01 [-0.07, 0.09] 0.80
Intercept 59.39 [56.44, 62.34] <0.001
1A Wald test for the study intervention interactions with weeks indicated a significant effect of the interventions over time (χ2(3) = 27.47, 
p<0.001). Data from BAN mothers with at least one maternal Hb measurement after two weeks postpartum were included: n=569 in control; n=316 
in mARV; n=573 in mLNS; n=308 in mLNS-mARV. mARV-LNS, maternal LNS/maternal ARV; mLNS, maternal LNS; mARV, maternal ARV; 
BAN, Breastfeeding, Antiretroviral and Nutrition; LNS, lipid-based nutrient supplement; ARV, antiretroviral drug.
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